Cost-effectiveness analysis of 10- and 13-valent pneumococcal conjugate vaccines in Peru

2.50
Hdl Handle:
http://hdl.handle.net/10757/582635
Title:
Cost-effectiveness analysis of 10- and 13-valent pneumococcal conjugate vaccines in Peru
Authors:
Mezones Holguín, Edward ( 0000-0001-7168-8613 ) ; Canelo Aybara, Carlos; David Clark, Andrew; Bess Janusz, Cara; Jaúregui, Bárbara; Escobedo Palza, Seimer; Hernandez, Adrian V. ( 0000-0002-9999-4003 ) ; Berhane, Yemane; Vega Porras, Denhiking; González, Marco; Fiestas, Fabián; Toledo , Washington; Michele, Fabiana; Suárez, Víctor J.
Publisher:
Elsevier B.V.
Journal:
Vaccine
Issue Date:
24-Nov-2015
URI:
http://hdl.handle.net/10757/582635
DOI:
10.1016/j.vaccine.2014.12.039
Additional Links:
http://www.sciencedirect.com/science/article/pii/S0264410X14016922
Type:
info:eu-repo/semantics/article
Rights:
info:eu-repo/semantics/openAccess
Language:
eng
Description:
Objective To evaluate the cost-effectiveness of introducing the 10-valent pneumococcal conjugate vaccine (PCV10) versus the 13-valent PCV (PCV13) to the National Immunization Schedule in Peru for prevention of pneumococcal disease (PD) in children <5 years of age. Methods The integrated TRIVAC vaccine cost-effectiveness model from the Pan American Health Organization's ProVac Initiative (version 2.0) was applied from the perspective of the Government of Peru. Twenty successive cohorts of children from birth to 5 years were evaluated. Clinical outcomes were pneumococcal pneumonia (PP), pneumococcal meningitis (PM), pneumococcal sepsis (PS) and acute otitis media from any causes (AOM). Measures included prevention of cases, neurological sequelae (NS), auditory sequelae (AS), deaths and disability adjusted life years (DALYs). A sensitivity analyses was also performed. Findings For the 20 cohorts, net costs with PCV10 and PCV13 were US$ 363.26 million and US$ 408.26 million, respectively. PCV10 prevented 570,273 AOM; 79,937 PP; 2217 PM; 3049 PS; 282 NS; 173 AS; and 7512 deaths. PCV13 prevented 419,815 AOM; 112,331 PN; 3116 PM; 4285 PS; 404 NS; 248 AS; and 10,386 deaths. Avoided DALYs were 226,370 with PCV10 and 313,119 with PCV13. Saved treatment costs were US$ 37.39 million with PCV10 and US$ 47.22 million with PCV13. Costs per DALY averted were US$ 1605 for PCV10, and US$ 1304 for PCV13. Sensitivity analyses showed similar results. PCV13 has an extended dominance over PCV10. Conclusion Both pneumococcal vaccines are cost effective in the Peruvian context. Although the net cost of vaccination with PCV10 is lower, PCV13 prevented more deaths, pneumococcal complications and sequelae. Costs per each prevented DALY were lower with PCV13. Thus, PCV13 would be the preferred policy; PCV10 would also be reasonable (and cost-saving relative to the status quo) if for some reason 13-valent were not feasible.; This study was presented at 9th International Symposium of Pneumococci and Pneumococcal Diseases, Hyderabad, India, March 2014, and supported by the National Council of Science, Technology and Technological Innovation of Peru (CONCYTEC) and International Clinical Epidemiology Network (INCLEN Trust)
Keywords:
Pneumococcal conjugate vaccine; Cost effectiveness; Disability adjusted life years; Children; Peru
ISSN:
0264-410X

Full metadata record

DC FieldValue Language
dc.contributor.authorMezones Holguín, Edwardes_PE
dc.contributor.authorCanelo Aybara, Carloses_PE
dc.contributor.authorDavid Clark, Andrewes_PE
dc.contributor.authorBess Janusz, Caraes_PE
dc.contributor.authorJaúregui, Bárbaraes_PE
dc.contributor.authorEscobedo Palza, Seimeres_PE
dc.contributor.authorHernandez, Adrian V.es_PE
dc.contributor.authorBerhane, Yemanees_PE
dc.contributor.authorVega Porras, Denhikinges_PE
dc.contributor.authorGonzález, Marcoes_PE
dc.contributor.authorFiestas, Fabiánes_PE
dc.contributor.authorToledo , Washingtones_PE
dc.contributor.authorMichele, Fabianaes_PE
dc.contributor.authorSuárez, Víctor J.es_PE
dc.date.accessioned2015-11-24T19:33:36Zes_PE
dc.date.available2015-11-24T19:33:36Zes_PE
dc.date.issued2015-11-24es_PE
dc.identifier.issn0264-410Xes_PE
dc.identifier.doi10.1016/j.vaccine.2014.12.039es_PE
dc.identifier.urihttp://hdl.handle.net/10757/582635es_PE
dc.descriptionObjective To evaluate the cost-effectiveness of introducing the 10-valent pneumococcal conjugate vaccine (PCV10) versus the 13-valent PCV (PCV13) to the National Immunization Schedule in Peru for prevention of pneumococcal disease (PD) in children <5 years of age. Methods The integrated TRIVAC vaccine cost-effectiveness model from the Pan American Health Organization's ProVac Initiative (version 2.0) was applied from the perspective of the Government of Peru. Twenty successive cohorts of children from birth to 5 years were evaluated. Clinical outcomes were pneumococcal pneumonia (PP), pneumococcal meningitis (PM), pneumococcal sepsis (PS) and acute otitis media from any causes (AOM). Measures included prevention of cases, neurological sequelae (NS), auditory sequelae (AS), deaths and disability adjusted life years (DALYs). A sensitivity analyses was also performed. Findings For the 20 cohorts, net costs with PCV10 and PCV13 were US$ 363.26 million and US$ 408.26 million, respectively. PCV10 prevented 570,273 AOM; 79,937 PP; 2217 PM; 3049 PS; 282 NS; 173 AS; and 7512 deaths. PCV13 prevented 419,815 AOM; 112,331 PN; 3116 PM; 4285 PS; 404 NS; 248 AS; and 10,386 deaths. Avoided DALYs were 226,370 with PCV10 and 313,119 with PCV13. Saved treatment costs were US$ 37.39 million with PCV10 and US$ 47.22 million with PCV13. Costs per DALY averted were US$ 1605 for PCV10, and US$ 1304 for PCV13. Sensitivity analyses showed similar results. PCV13 has an extended dominance over PCV10. Conclusion Both pneumococcal vaccines are cost effective in the Peruvian context. Although the net cost of vaccination with PCV10 is lower, PCV13 prevented more deaths, pneumococcal complications and sequelae. Costs per each prevented DALY were lower with PCV13. Thus, PCV13 would be the preferred policy; PCV10 would also be reasonable (and cost-saving relative to the status quo) if for some reason 13-valent were not feasible.es_PE
dc.descriptionThis study was presented at 9th International Symposium of Pneumococci and Pneumococcal Diseases, Hyderabad, India, March 2014, and supported by the National Council of Science, Technology and Technological Innovation of Peru (CONCYTEC) and International Clinical Epidemiology Network (INCLEN Trust)es_PE
dc.formatapplication/pdfes_PE
dc.language.isoenges_PE
dc.publisherElsevier B.V.es_PE
dc.relation.urlhttp://www.sciencedirect.com/science/article/pii/S0264410X14016922es_PE
dc.rightsinfo:eu-repo/semantics/openAccesses_PE
dc.sourceUniversidad Peruana de Ciencias Aplicadas (UPC)es_PE
dc.sourceRepositorio Académico - UPCes_PE
dc.subjectPneumococcal conjugate vaccinees_PE
dc.subjectCost effectivenesses_PE
dc.subjectDisability adjusted life yearses_PE
dc.subjectChildrenes_PE
dc.subjectPerues_PE
dc.titleCost-effectiveness analysis of 10- and 13-valent pneumococcal conjugate vaccines in Perues_PE
dc.typeinfo:eu-repo/semantics/articlees_PE
dc.identifier.journalVaccinees_PE
dc.description.fundingThis study was made possible through the financial support of the Instituto Nacional de Salud (National Institute of Health, Lima, Peru) and the PROVAC Initiative of the Pan American Health Organization (Washington, DC, USA).es_PE
All Items in UPC are protected by copyright, with all rights reserved, unless otherwise indicated.